Please ensure Javascript is enabled for purposes of website accessibility

1 Innovative Growth Market on the Verge of Collapse

By Dan Carroll – Jan 26, 2014 at 10:30AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Hypertension treatment renal denervation has been a hot topic in the medical device industry, but a recent trial disappointment from Medtronic has companies like Covidien and Boston Scientific backpedaling.

Innovation's a key now more than ever in the medical device industry, which has been slammed by the combination of slumping prices, tough competition, and tightening hospital budgets. For top cardiovascular device makers like Covidien (COV.DL) and Medtronic (MDT 2.48%), finding new treatments for growing health problems is the way to future sales -- and few developmental treatments have impressed investors and analysts recently in this industry like hypertension treatment renal denervation.

Yet renal denervation has stumbled onto hard times all of the sudden. A pivotal trial in the niche from Medtronic's Symplicitydevice ended in failure. Now Covidien recently announced that it will cease making its own European regulator-approved renaldenervation device, the OneShot, and fellow cardiovascular leader Boston Scientific (BSX 2.79%) is putting its own trial on hold until it can review Medtronic's data.

Is renal denervation dead in the water for innovation-minded device makers? In the video below, Motley Fool contributor Dan Carroll takes you through what you need to know about the stunning fall of this once-red hot growth niche -- and whether or not renal denervation can still become a promising part of medical device makers' portfolios.

Fool contributor Dan Carroll has no position in any stocks mentioned. The Motley Fool recommends Covidien. The Motley Fool owns shares of Medtronic. We Fools may not all hold the same opinions, but we all believe considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.